Zai Lab Ltd (ZLAB.OQ) saw its shares plummet 5.21% in pre-market trading on Friday after the biopharmaceutical company reported a wider-than-expected loss for the fourth quarter and revenue that fell slightly short of Wall Street estimates.
The company reported an adjusted loss of $0.80 per share for the quarter ended December 31, higher than the analyst consensus estimate of a $0.65 loss per share. Revenue rose 64.8% year-over-year to $108.51 million, but missed analysts' expectation of $110.21 million.
Despite the disappointing quarterly results, analysts remain optimistic about Zai Lab's prospects, with 12 out of 12 analysts rating the stock as a "buy" or "strong buy." The average consensus price target for the stock stands at $50.00, representing significant upside potential from its current levels.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。